Stockscreener 앱 받기
174.79
4.00%
-7.28
시간 외 거래:
174.00
-0.79
-0.45%
전일 마감가:
$182.07
열려 있는:
$179
하루 거래량:
751.74K
Relative Volume:
0.84
시가총액:
$8.42B
수익:
$4.02B
순이익/손실:
$-142.16M
주가수익비율:
-59.12
EPS:
-2.9563
순현금흐름:
$518.49M
1주 성능:
+11.52%
1개월 성능:
+5.43%
6개월 성능:
+0.02%
1년 성능:
+29.44%
1일 변동 폭
$172.17
$181.76
1주일 범위
$157.87
$184.83
52주 변동 폭
$132.65
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
174.79 | 8.77B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
482.08 | 183.60B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
176.11 | 127.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
550.82 | 44.71B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.05 | 38.38B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
371.93 | 37.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories International Inc (CRL) Shares Fall 4.0% -- What GF Score of 72 Tells Investors - GuruFocus
CRL (CRL) CFO Glenn Coleman receives 6,640-share equity grant at $180.71 - Stock Titan
CRL (NYSE: CRL) CIO receives stock grant; shares withheld for taxes - Stock Titan
Charles River (NYSE: CRL) EVP awarded 5,257 shares, 979 withheld - Stock Titan
CRL (NYSE: CRL) SVP Michael Knell awarded 1,837 shares, 200 used for tax withholding - Stock Titan
Charles River (NYSE: CRL) CEO awarded shares, withholds stock to pay tax - Stock Titan
James C. Foster (CRL) records tax-withholding share disposition and updates indirect holdings - Stock Titan
Charles River (NYSE: CRL) EVP gets 5,135-share award with tax withholding - Stock Titan
Charles River (NYSE: CRL) executive reports stock grant and tax withholding - Stock Titan
CRL: Operational efficiency, innovation, and portfolio focus drive growth and resilience - TradingView
CRL: Modernization, AI, and NAMs drive growth and margin expansion, with renewed DSA momentum - TradingView
Charles River Shareholder Notice - TMX Newsfile
Charles River Laboratories to Present at William Blair and Jefferies Conferences 2026 - BioSpace
Charles River Laboratories (CRL) to Present at Key Investor Conf - GuruFocus
Charles River Laboratories to Present at William Blair and Jefferies Conferences - pharmiweb.com
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
CLSA upgrades Charles River Laboratories International (CRL) - MSN
Charles River Laboratories Hits Day High with 10.24% Surge in Stock Price - Markets Mojo
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MSN
CLSA upgrades Charles River Labs stock rating on regulatory outlook - Investing.com UK
CLSA upgrades Charles River Labs stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
Top Charles River Laboratories International (CRL) Competitors 2026 - MarketBeat
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity - Stock Titan
Charles River (NYSE: CRL) executive logs tax-share withholding and trust gift - Stock Titan
Charles River Laboratories International Jumps 7.9% in Broad Rally - AlphaStreet
CRL (CRL) CEO Girshick delivers 618 shares for tax withholding, holds over 71K - Stock Titan
Charles River (NYSE: CRL) finance executive reports small tax-withholding share moves - Stock Titan
Charles River (CRL) EVP LaPlume reports 428-share tax-withholding disposals - Stock Titan
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Are Wall Street analysts bullish on Charles River Laboratories stock? - MSN
Are Wall Street Analysts Bullish on Charles River Laboratories Stock? - Barchart.com
Charles River Laboratories Inte (CRL) Stock Analysis: A 30% Upside Potential Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Cell Banking Outsourcing Market: 16%+ CAGR (2026-2031), Expanding with Rising Demand for Biologics and Regenerative Medicine Services, Says Mordor Intelligence - GlobeNewswire Inc.
Is Charles River (CRL) Quietly Recasting Its Moat Around AI Pathology And Cell Therapy Services? - Yahoo Finance
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)? - simplywall.st
Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness - simplywall.st
Inspired Announces CFO Transition - The Manila Times
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MSN
The 5 Most Interesting Analyst Questions From Charles River Laboratories’s Q1 Earnings Call - Yahoo Finance
Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook - MSN
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform - simplywall.st
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
1.15%
자본화:
|
볼륨(24시간):